A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid hormone plays a key role in the development and progression of prostate cancer.

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...